#United States #San Rafael #BioMarin #POMBILITI #OPFOLDA

BioMarin's Recent Announcement: Five-Year Phase 3 Data

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has recently disclosed compelling results regarding the safety and efficacy of their combination therapy, POMBILITI® (cipaglucosidase alfa-atga) and OPFOLDA® (miglustat), for patients with late-onset Pompe disease (LOPD) at the 31st Annual Congress of the World Muscle Society (WMS) held in Hiroshima, Japan. This presentation highlighted the findings from the PROPEL open-label extension (OLE) study, showcasing encouraging outcomes over a five-year follow-up period.

The findings emerged from a cohort of 82 participants who had received continuous treatment with both POMBILITI and OPFOLDA, combining data from those who had previous enzyme replacement therapy (ERT) experiences as well as those who were ERT-naïve. Historically, this disease affects muscle strength and respiratory functions over time, leading to worsening conditions without effective treatment. This long-term study sheds light on sustained motor function and stabilization of pulmonary functions, crucial for patients living with this progressive condition.

Key Findings of the Study

The data revealed significant results:

• - For patients with a prior history of ERT, there was a mean change of 0.7% in the six-minute walk distance (6MWD) and a drop of 2.8% in their forced vital capacity (FVC).
• - Conversely, the ERT-naïve group exhibited a more pronounced improvement, with a mean change of 10.5% in 6MWD and a slight decrease of 4.4% in FVC.

Dr. Greg Friberg, Executive Vice President and Chief Research Development Officer at BioMarin, stated, “These five-year results demonstrate that POMBILITI and OPFOLDA can provide durable, long-term benefits for people living with late-onset Pompe disease.” He emphasized the importance of these findings, especially considering the complexities of managing a progressive genetic disorder.

The safety profile was also promising. While 51.2% of participants experienced treatment-related adverse events, the majority were manageable, reaffirming the therapeutic potential of this treatment option.

Additional Research: Nivudirsen (BMN 351)

Alongside the pivotal results for POMBILITI and OPFOLDA, BioMarin presented additional data on Nivudirsen (BMN 351), an investigational therapy for Duchenne muscular dystrophy (DMD). The studies indicated favorable treatment tolerability and positive outcomes pertaining to dystrophin expression, a protein essential for muscle health, which was highlighted in multiple presentations during the congress.

Phase 1/2 results showed promising outcomes across various measures, suggesting that this therapy could soon evolve into a viable option for young boys suffering from the severe neuromuscular condition.

The Importance of Continuous Research

BioMarin’s recent findings reiterate a strong commitment to providing innovative medical solutions aimed at rare diseases. The ongoing clinical trials and studies reflect the dedication to progress within biotechnology, potentially altering the clinical landscape for Pompe disease and DMD patients. Updated insights from the followME Pompe Journey Registry must be closely monitored to ensure a greater understanding of the disease burden.

The PROPEL OLE study stands as a key component in mapping out the long-term outcomes for adults with LOPD on this combination treatment, further establishing BioMarin's role as a leader in the rare disease space.

Looking Ahead

As BioMarin continues its research and development, the medical community remains optimistic that these advances will support improved patient outcomes in both late-onset Pompe disease and Duchenne muscular dystrophy. Updates from the respective trials will facilitate better-informed healthcare decisions for clinicians and caregivers, ultimately enhancing the quality of life for those affected.

For further information, researchers, patients, and healthcare providers can explore relevant clinical trials and studies on BioMarin’s official website or reach out for support through BioMarin RareConnections®.